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 I 
Preface 
In this thesis, the aim was to investigate circumstances surrounding chemotherapy 
treatment for bladder cancer at the University Hospital of North Norway. Knowing that 
neoadjuvant chemotherapy increases survival of these patients, I wanted to find out how 
many of patients with bladder cancer are treated with neoadjuvant chemotherapy at this 
hospital. My work on this thesis started in the fall of 2019 during my fourth year at medical 
school and continued to June of 2021, as I finished my fifth year as medical student.  
 
I previously had minimal experience with both bladder cancer and writing a thesis prior to 
this. Throughout this process I have learned a great deal about both. It has been a fun and 
interesting subject to work with, which I have enjoyed. This new interest for oncology led me 
to applying for work as medical student with temporary license at the Oncology Department 
at the University Hospital of North Norway, where I started working in March of 2021.  
 
My resources for this project were the medical record program for patients at the hospital 
and literature available from the University Library. I registered clinical data for alle patients 
included in the study and performed simple descriptive statistics on my own, while my 
supervisor helped me with the more advanced statistical work. I received no external 
funding for this project. 
 
I would like to thank my main supervisor professor in oncology Hege Sagstuen Haugnes, for 
whom this project could not have been done without. She has contributed with her great 
knowledge in oncology and excellent guidance in scientific research and writing. I would also 
like to thank my co-supervisor urologist, PhD Eivind Bjerkaas for his contribution to this 
thesis with his knowledge of surgical aspects. 
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Introduction: Previously, radical cystectomy alone has been the standard treatment for 
localized, muscle invasive bladder cancer (MIBC), with the introduction of neoadjuvant 
chemotherapy (NAC) in 2011 in Norway. Outcome advantages for patients receiving NAC are 
thoroughly documented. Our primary aim with this study was to investigate whether 
patients treated for MIBC at UNN during 2011-2019 were offered NAC. Secondary, we 
wanted to evaluate feasibility, side effects and efficacy of NAC, along with surgical 
complications and survival.  
 
Material and method: This study included 154 patients with urothelial carcinoma in bladder 
cystectomized at the University Hospital of North Norway (UNN) in the years 2011-2019 who 
were identified by looking up procedure codes in the medical record program DIPS. Of these, 
99 (MIBC) and were considered for NAC. NAC consisted of three cycles of methotrexate, 
vinblastine, doxorubicin and cisplatin (MVAC) given every second week. 
 
Results: Out of the MIBC patients, 47.5% received NAC. This number increased significantly 
during the study period, from 29.3% in the years 2011-2014, to 60.3% in the years 2015-
2019. Old age was the most frequent reason for not receiving NAC, accounting for 50%, 
followed by reduced kidney function and heart disease, both making up 9.6%. Overall, 57.4% 
and 75.1% completed all three cycles and two cycles of chemotherapy, respectively. Most 
common reasons for discontinuation were reduced kidney function or infection. 
Neutropenic sepsis was seen in 17% of patients. Amongst the 27 patients who completed all 
three rounds, 56% did not experience any complications throughout chemotherapy. The 
actuarial 2-year overall survival was numerically higher for patients treated with NAC (78%; 
95% CI 66%-90%) than those without NAC (58%; 95% CI 43%-72%). 
 
Conclusion: Chemotherapy coverage at UNN was high compared to other studies. Feasibility 





AC – Adjuvant chemotherapy 
BCG – Bacillus Calmete-Guérin 
BMI – Body mass index 
COPD – Chronic obstructive pulmonary disease 
CT – Computed tomography 
G-CSF – Granulocyte colony-stimulating factor 
GFR – Glomerular filtration rate 
HR – Hazard ratio 
MSH2 – MutS homolog 2 
MIBC – Muscle-invasive bladder cancer 
MVAC – Methothrexate, Vinblastine, Adriamycin, Cisplatin 
NAC – Neoadjuvant chemotherapy 
NMIBC – Non-muscle-invasive bladder cancer 
TURB – Transurethral resection of bladder 




Bladder cancer is currently the fourth most common cancer type in Norway amongst men, 
and seventh in total when including both genders, with approximately 1500 new cases each 
year (1). Men make up about three out of four of these cases. The incidence for men in 2019 
was around 50 per 100 000, with a stable incidence since the early 1990s (Figure 1). Prior to 
1990, the incidence for men had been steadily increasing. For women the incidence for 2019 
was about 15 per 100 000 (Figure 2). This number increased gradually until 10 years ago, 
after which it has flattened out. As for survival rates, these have been increasing in Norway 
for the past 50 years for both genders (2). The five-year relative survival for patients 
diagnosed in the period 2010-2014 was 76.3% for men and 70.1% for women (1). Median 
age at diagnosis in Norway in 2018 was 72 years for men and 74 for women (3). 
 
There are several known risk factors in bladder cancer. Among modifiable risk factors, 
smoking is strongest related, with some studies showing 40-50% of bladder cancer cases in 
both men and women being smoking-related (4, 5). There are also a multitude of other 
chemicals that increase the risk of bladder cancer, but to a lesser degree (6). Genetic 
predisposition has been shown in several studies. Most notably, patients with Lynch 
syndrome carrying an MutS homolog 2 (MSH2) mutation have an increased lifetime risk of 
developing urothelial cancer. The increased risk is greater for men than women (7, 8). In 
Norway, the national guidelines recommend that members of families with Lynch Syndrome 
and history of urothelial cancer should be screened yearly with urinary stix and cytology 
from the age of 35. Urothelial cancer secondary to prior cancer treatment has been studied 
in recent years. A large meta-analysis has shown that radiation treatment of prostate cancer 
increases the relative future risk of developing bladder cancer by 67%, but with a modest 
increase in the absolute risk (9). 
 
Diagnostics and histology 
In the early stages of bladder cancer there are usually relatively few symptoms, with the 
most common one being hematuria (10). Gross hematuria (visible blood in urine) without 
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known cause is always referred to an urologist, while microscopic hematuria (blood in urine 
that is not visible) is only referred for patients above 50 years old with risk factors and/or 
symptoms and no known cause. In Norway, there is a standard set diagnostic pathway called 
“pakkeforløp” for patients that meet the aforementioned criteria. This pathway secures a 
standardized and predictable diagnostic work-up within given time limits for patients with 
suspected cancer. For bladder cancer, the guidelines for the pathway recommend that once 
patients are referred, they should be seen by a specialist and have initial investigations done 
within seven days. After these investigations, the further treatment course should be 
decided within 25 days, and after this decision is made, the chosen treatment option should 
commence within 14 days. Put in simpler terms, treatment must start within 46 days from 
when the referral is received (3). 
 
Initial investigations for bladder cancer include cystoscopy and Computed tomography (CT) 
scan. Any tumor found during cystoscopy are biopsied with a method called transurethral 
resection of bladder (TURB), which is a procedure where cancer suspicious tissue in the 
bladder is removed. The material from this procedure is analyzed by a pathologist, and 
combined with CT scans, determines the tumor stage. In some cases of early-stage bladder 
cancer, TURB is curative treatment in itself. 
 
Histologically, urothelial carcinomas are the dominant type, making up about 90% of bladder 
cancers (11). Squamous cell carcinomas are second most abundant, followed by 
adenocarcinomas. Sarcomas and lymphomas are also seen. We will only describe the 
urothelial carcinomas later on in this report. Bladder tumors are staged according to the 
TNM-system, which grades the tumor from T1 to T4(3). In addition, superficial in situ 
urothelial carcinoma are classified as Tis. Tumors that only invade the subepithelial 
connective tissue of the bladder are classified as T1. If the tumor penetrates the muscular 
layer surrounding the bladder (muscularis propria), it is classified as T2. These are also 
further divided into T2a and T2b, for respectively superficial and deep penetration of the 
muscle layer. T3 tumors invade soft tissue surrounding the bladder and are subcategorized 
as T3a if invasion is only microscopically detectable and T3b if macroscopically detectable. If 
the tumor invades surrounding organs it is classified as T4. Bladder cancer with T2 or more 
advanced tumor stage is collectively termed muscle-invasive bladder cancer (MIBC), while 
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Treatment will vary according to tumor stage. For patients with NMIBC, the TURB can be 
sufficient treatment if all tumor tissue is removed, but some of them will need additional 
treatment consisting of instillation of Mitomycin-C or Bacillus Calmette-Guérin (BCG) into 
the bladder via a transurethral catheter. Mitomycin-C is a chemotherapeutic agent and BCG 
an immunotherapeutic agent. Studies have shown that instillation of Mitomycin-C within a 
few hours after TURB reduces the risk of recurrence by up to 35% in low-grade NMIBC (12-
15). For those with intermediate risk tumors, immediate instillation of Mitomycin-C, 
followed by regular treatment with instillation of Mitomycin-C or BCG has proven to be 
effective (16-21). The instillations are given weekly for six weeks and then monthly for a full 
year. Further treatment effect after one year is not thoroughly documented, but some 
receive BCG-instillations for up to three years. BCG is currently the first choice for patients 
with intermediate and high-risk tumors. In some few cases of NMIBC, radical cystectomy will 
be required. For patients with localized MIBC, radical cystectomy plus pelvic lymph node 
dissection is the standard treatment. Patients who are not able or willing to undergo surgery 
can be offered radiotherapy, or preferably trimodal treatment (maximal TURB, 
chemotherapy and radiotherapy) (3). Treatment of metastatic disease is beyond the scope 
of this study and will not be described. 
 
MIBC has been proven to be highly chemotherapy sensitive and studies show that patients 
with localized/locally advanced MIBC who receive chemotherapy in addition to cystectomy 
have a greater survival-rate (22-26). In general, when giving chemotherapy as an addition to 
surgery you must decide whether to give it before (neoadjuvant chemotherapy (NAC)) or 
after (adjuvant chemotherapy (AC)) the surgery. Both NAC and AC have shown better results 
vs cystectomy alone. NAC is currently preferred due to better documented effect and that 
patients who receive chemotherapy after surgery cannot tolerate the chemotherapy as well 
and on average finish less cycles of chemotherapy (27). 
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Cisplatin has proven to be the most effective cytostatic agent in bladder cancer (26). Three 
cycles of cisplatin-based NAC increases the overall 5-year survival-rate from 45 to 50% (all 
stages included) in patients with locazlied/locally advanced MIBC, according to studies (22-
26). The relative increased survival rate is higher the more advanced the cancer is (22, 28). 
These results have led to both international and national guidelines recommending that all 
patients with MIBC are considered for NAC in addition to cystectomy. In Norway, these 
guidelines were implemented in 2011.  
 
Treatment with dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), 
where a total of three cycles of chemotherapy are given every second week, has shown to 
be very feasible, with patients ready for surgery as early as seven to eight weeks after the 
first cycle of chemotherapy (29, 30). This has been, and currently still is, the standard 
regimen used at the University Hospital of North Norway (UNN) for neoadjuvant treatment 
of bladder cancer. The treatment effect is evaluated with a CT scan after two cycles of dose-
dense MVAC. 
 
As with most chemotherapy treatments, this treatment can be very tough on the patients, 
with considerable risk of side effects such as neutropenic infection, neuropathy, nausea and 
malnutrition. The patients who are being considered for this treatment are therefore 
discussed at a multidisciplinary meeting, consisting of specialists from several departments, 
to determine if NAC is likely to be beneficial for the patients. In general, the treatment is not 
recommended for patients above 75 years old or those with comorbidities such as reduced 
kidney function and cardiovascular disease. The reason it is not recommended for patients 
with reduced kidney function is because of cisplatin, which is very nephrotoxic. In addition, 
cisplatin is poorly tolerated among older patients and it should be used with caution in 




Radical cystectomy is often associated with complications. In a large study including 1142 
patients who underwent radical cystectomy in the period 1995-2005, 64% of the patients 
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had some degree of complication within the first 90 days after surgery (31). The 
complications were graded using the Clavien-Dindo classification system (32) and showed 
that 51% of patients experienced grade 1-2 complications and 13% grade 3-5 complications. 
The most common complications were gastrointestinal and infectious, making up 29% and 
25% respectively. More recent studies have showed that the complication frequency is not 
higher in patients who receive NAC prior to cystectomy versus those who do not (33). 
 
Aims of the study 
NAC before cystectomy as a treatment option for localized/locally advanced MIBC was 
gradually introduced in Norway and UNN from 2011. We did not know to what extent this 
treatment was offered to patients treated at UNN prior to this research, nor did we know 
anything about the outcome for patients who received the treatment. Studies show that too 
few patients with MIBC are offered NAC, despite its proven effect (34, 35).  
 
The main aim of this study was to investigate whether patients who were treated for 
localized/locally advanced MIBC at UNN during 2011-2019 were offered NAC, and reasons 
for not being offered such treatment. Secondary aims include evaluating the feasibility, side 
effects and efficacy of the NAC, including effects of NAC on weight and kidney function. 
Finally, we wanted to study surgical complications and survival with NAC plus cystectomy 
versus cystectomy alone. 
  
Material and method 
Patient selection and treatment 
All patients who were cystectomized at UNN in the period 01.01.2011-31.12.2019 were 
identified by looking up procedure codes in the medical record program DIPS (N=199, flow 
chart). Inclusion criteria included patients who had a curative cystectomy for urothelial 
carcinoma in the bladder. Consequently, patients who were cystectomized for other reasons 
than bladder cancer, had other histology than urothelial carcinoma or were cystectomized 
for palliative purposes were excluded from this study (flow chart). After these exclusions, 
the total number of patients included in the study was 154. 
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Since only patients with MIBC are treated with NAC, we wanted to look at this patient group 
when comparing data in relation to chemotherapy. Out of the 154 patients, 99 (64.3%) had 
muscle-infiltrating bladder cancer (T2 or more advanced, determined by looking at both 
histology and CT images). We wanted to see how the NAC coverage developed over the 
years we studied. For this, we chose to compare the first four years (2011-2014) to the last 
five years (2015-2019) combined. The reason for this is that some of the individual years did 
not have enough patients to give a representative picture. 
 
Neoadjuvant chemotherapy consisted of in total three cycles of MVAC given every second 
week if the treatment was well tolerated. Each cycle consisted of methotrexate 30 mg/m2 
day one, and vinblastine 3 mg/m2, doxorubicin 30 mg/m2 and cisplatin 70 mg/m2 on day 
two. In case of creatinine clearance < 60 ml/min/1.73m2, the cisplatin dose was given over 
two days (35 mg/m2 on days one and two).  Growth-colony stimulating factor (G-CSF) was 
given at day four. The patients underwent a radiological evaluation with CT or MRI scan prior 
to the third cycle. In case of radiological progression, the third cycle was cancelled and the 
patient went directly to surgery. 
 
A radical cystectomy includes removal of the bladder plus prostate and seminal vesicles in 
men, and removal of the bladder plus uterus and adnexa in women, and in addition a pelvic 
lymph node dissection. A urinary diversion is always performed, most commonly as an ileac 
conduit (3). Surgery was exclusively performed as open surgery until the fall of 2019, with 
the gradual implementation of robotic-assisted laparoscopic surgery from this point on. 
 
Variables 
The following data was collected from the medical records: patient characteristics including 
age, gender, height, weight and smoking status, tumor stage (histological and radiological) at 
date of diagnosis and after cystectomy, creatinine levels during chemotherapy and before 
cystectomy, complications and feasibility of chemotherapy, date of surgery, complications 
after surgery, time spent in hospital after surgery, cancer recurrence status and outcome for 
all patients up to the date of this study. 
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Relative weight change was calculated for all patients who initiated NAC as ((weightcystectomy-
weightchemotherapy)/weightchemotherapy) x 100%. Relative weight change was categorized as 
moderate gain (>5%), small gain (3% to <5%), maintenance (+/- <3%), small loss (3% to 5%) 
and moderate loss (> 5%), as described previously (36). Body mass index (BMI) was 
calculated as weight (in kg) divided by height (in meters) squared.  
 
Creatinine clearance was calculated based on age and serum creatinine (37), and 90 
ml/min/1.73m2 was used as cut-off for slightly decreased renal function (38). In addition, 
Creatinine clearance < 60 ml/min/1.732 was used to identify those with moderately 
decreased kidney function. 
 
Surgical complications were quantified using the Clavien-Dindo classification system (32), 
which is a scoring system where complications are categorized from 1-5 on a severity scale. 
We chose to simplify this by putting grade 1-2 complications together in one group and 
grade 3-5 together in another. Complications were identified at two different intervals after 
cystectomy, the first within 30 days and the other within six months. We also chose to 
investigate how many of the patients had an infection within 30 days after the operation. 
 
Statistics 
Continuous variables are presented as median (range), and categorial variables are 
presented as counts (proportion). Comparisons between the NAC and the no NAC group 
were performed using Chi square test for categorical variables, and Mann Whitney U test for 
continuous variables. Comparisons between median values (e.g. weight) at start 
chemotherapy and at cystectomy within the NAC group were performed with the Wilcoxon 
matched pairs signed rank sum test. The overall observation time in years was calculated 
from date of cystectomy until death or end of follow up (as of June 2020). Time was 
calculated in days from initiation of the first chemotherapy cycle until cystectomy, and in 
months from cystectomy until relapse for relapsing patents. 
 
Cumulative survival was calculated with the Kaplan-Meier method. Cox regression was used 
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to assess the association between NAC vs. no NAC and risk of relapse and overall mortality, 
presented as hazard ratio (HR) and 95% confidence interval (95%CI), adjusted for age and 
tumor stage pre-cystectomy. A test of parallel lines confirmed that the proportional hazard 
assumption was met. Statistical analyses were performed using the SPSS 26.0 package (SPSS 
Inc., Chicago IL, USA). Two-sided p-values <0.05 were considered significant. 
 
Ethics 
The study was approved by the data protection officer at UNN (project number 02386). 
 
Results 
Study patient characteristics 
Overview of patient characteristics at cystectomy for all included patients are presented in 
table 1. Of the 154 patients included, 120 (77.9%) were male and 34 (22.1%) female. Overall, 
42 (27.3%) were current smokers, 71 (46.1%) ex-smokers and 39 (25.3%) never smokers. 
Median age was 71.8 years (range 42.5-92.6). Median creatinine was 93.5 µmol/L (range 47-
212). Median weight 77.5 kg (range 49.7-122). 
 
In total, 99 of the 154 patients included in this study had MIBC and thus were considered for 
NAC. The remaining 55 patients had less advanced cancer, in which case guidelines do not 
recommend chemotherapy. These 55 patients were included in analyses of surgical 
complications, but not in analyses regarding chemotherapy coverage, effects, complications, 
relapse and survival. 
 
Chemotherapy implementation/coverage 
Overall, 47 (47.5%) of the 99 patients with MIBC received NAC. Patient characteristics 
according to NAC vs. no NAC is presented in table 2. Patients who received NAC were 
younger at cystectomy than those without NAC (median age 68 years vs. 75 years, p-value 
<0.001), otherwise there were no statistically significant differences in patient characteristics 
presented in table 2 between these two groups. For the remaining 52 (52.5%) of those with 
MIBC, the most frequent reason for not receiving chemotherapy was old age, accounting for 
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50% of the cases (table 3). Other frequent reasons were reduced kidney function (9.6%) and 
heart disease (9.6%). Overall, 13.5% were contributed to other comorbidities than heart or 
kidney disease, such as chronic obstructive pulmonary disease (COPD), obesity and other 
concurrent malignancy. The remaining 17.3% were grouped as “Other reasons” and 
consisted mainly of cases where there was no obvious reason found in the patient journal, 
but also one case with an emergency cystectomy and one where the patient did not want 
chemotherapy. All cases where there was no clear reason for not receiving NAC described in 
the medical records happened prior to 2014.  
 
Since the introduction in 2011 there has been a steady increase in the number of patients 
who received NAC. In the first years from 2011 through 2014, only 12 of 41 (29.3%) patients 
received NAC. From 2015 through 2019, the amount was 35 out of 58 (60.3%) (table 4). After 
excluding patients aged above 75 years, the percentage of patients who received NAC were 
overall 63.4% (45 out of 71 patients). The number increased from 36.7% (11 out of 30 
patients) during 2011-2014 to 82.9% (34 out of 41 patients) in the years 2015-2019. 
 
Chemotherapy feasibility and side-effects 
For those who received NAC, 27 (57.4%) received all three chemotherapy cycles, while seven 
(14.9%) patients discontinued after cycle one and another thirteen (27.7%) after cycle two 
(table 5). Of the seven who discontinued after cycle one, four (57.1%) were because of 
reduced kidney function. Among those ones who dropped out after cycle two, the reasons 
were more diversified, with infection responsible for four out of 13 (30.8%), 
nausea/anorexia three out of 13 (23.1%) and increased creatinine/reduced kidney function 
two out of 13 (15.4%). One of the patients only received two cures because the evaluation 
after two cures showed significant remission and the patient was deemed ready for surgery. 
The remaining four patients were categorized as others, further described under table 5. 
 
During the first cycle of chemotherapy, 24 patients 51.1% did not experience any 
complications. For cycle two and three the percentage without severe complications was 
65% and 81.5% respectively. The most common complications were nausea/anorexia and 
neutropenic sepsis for all three cycles (table 6). Neutropenic sepsis occurred in 6 patients 
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(12.8%) after cycle one, 3 (7.5%) after cycle two and 2 (11.1%) after cycle three, despite the 
prophylactic use of G-CSF. Worth noting is that four patients experienced neutropenic sepsis 
after more than one cycle. Overall, of the 47 patients who received NAC, 8 (17%) had 
neutropenic sepsis at some time during chemotherapy. There were no deaths related to 
complications during chemotherapy. Among the 27 patients who completed all the cycles, 
15 (56%) did not have complications after any of the cycles. Median time from first 
chemotherapy cycle until cystectomy was 52 days (range 28-76). 
 
Median weight at start of chemotherapy for all 47 patients was 81 kg (range 55-114), and it 
decreased to 76 kg (range 53-114) at cystectomy (p<0.001). In total 25 patients (53%) had a 
small weight gain or stable weight from chemotherapy initiation to cystectomy, while 22 
(47%) experienced a weight loss, of whom 14 (30%) had a moderate weight loss. Median 
BMI was 25.5 kg/m2 (range 19-35) at start chemotherapy and decreased to 24.6 kg/m2 
(range 19-35) at cystectomy (p<0.001).  
 
Median creatinine for all 47 patients was 86 μmol/L (range 54-129) at start of chemotherapy 
and increased to median 90 μmol /L (range 61-200) at cystectomy (p<0.001). Creatinine 
clearance was median 79 (range 45-123) at start of chemotherapy and decreased to median 
72 (range 29-110) at cystectomy (p=0.041). The number of patients with slightly decreased 
renal function increased from 35 (75%) at start chemotherapy, to 41 (87%) at cystectomy. 
The number of patients with moderately decreased renal function increased from 11 (23%) 
at start of chemotherapy to 14 (30%) at cystectomy. 
 
Efficacy of chemotherapy 
Prior to chemotherapy, 42 of the patients (89%) had histologically T2 or more advanced 
cancer in the biopsies (figure 3). The remaining five patients with histologically pTis or pT1 
were considered to have radiological T2 stage and were thus offered NAC. After 
chemotherapy, the percentage of patients with pT2 or more advanced cancer was reduced 
to 51% (24 out of 47). Overall, 13 patients (28%) were downgraded to pT0 (pathologic 
complete response). A total of 23 patients (49%) had a histological downgrading of the 




The surgical complications for patients in this study are presented in table 7. Infection was 
the most frequent complication for all categories. Other frequent complication categories 
were gastrointestinal, bleeding/anemia, heart/circulatory, wound rupture and kidney failure. 
Among all 154 patients included, 53.2% experienced any grade 1-2 complications and 24% 
any grade 3-5 complications within 30 days. Overall, 60.4% had any grade 1-2 complications, 
and 29.2% any grade 3-5 complications within six months.  
 
No NAC patients had a slightly higher prevalence of grade 1-2 complications within 30 days 
(55% vs. 48.9%, p=0.38), but it was not statistically significant. For grade 3-5 complications in 
the same time period, numbers were almost equal (24.3% vs 23.4%). Grade 1-2 
complications within six months were also quite similar for NAC vs no NAC (57.4% vs 61.7%). 
The NAC group had a higher frequency, although not significant, of any grade 3-5 
complications within six months (34% vs. 27.4%, p=0.36). 
 
Relapse and survival 
Overall, 55 (55%) of included patients were alive at the end of follow-up (table 8). A total of 
30 patients (including two patients who never were tumor-free after surgery) had 
experienced recurrence at end of follow-up (June 2020). Of these 30, five had recurrence 
only in regional lymph nodes, two only in liver, one only in lungs and the remaining 22 in 
multiple regions/organs. Median time to relapse was 10.5 (range 1.8-66.5) months after 
cystectomy. Age-adjusted Cox-regression showed that NAC compared with no NAC did not 
influence the risk of relapse (HR for relapse 0.80, 95% 0.36-1.77), while increasing pre-
cystectomy tumor stage was associated with risk for relapse (p for trend 0.003).  
 
The actuarial 2-year overall survival was 68% for all patients (95% CI 58%-77%), and it was 
numerically higher for patients treated with NAC (78%; 95% CI 66%-90%) than those without 
NAC (58%; 95% CI 43%-72%), but not statistically significant (overlapping Cis). Bladder cancer 
was the most common cause of death for both patient groups. In the NAC group, 13 patients 
(27%) died because of bladder cancer, while in the no NAC group 14 patients (27%) died due 
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to bladder cancer. A considerable larger proportion of patients with no NAC compared with 
NAC died of treatment-related complications (14% vs. 2%, not possible to perform significant 
testing due to only one observation in the NAC group). Age-adjusted Cox regression showed 
that NAC compared with no NAC did not influence overall survival (HR for death 0.68, 95% 
0.35-1.32) (figure 4), and increasing pre-cystectomy tumor stage was not associated with 




This study showed that the total NAC coverage in the time period 2011-2019 at UNN was 
47.5%. Since this number increased drastically during the study time period, it probably does 
not represent to what extent NAC is currently offered to patients with MIBC. For the first 
four years after implementation the total coverage was as low as 29.3%, rising to 60.3% for 
the last five years. There may be several reasons as to why the coverage was so low in the 
first years. Firstly, this was a newly implemented treatment option, and as with most new 
treatments, there will always be some skepticism and reluctancy, especially when there 
already are well established treatment options. It is also normal for new treatments to be 
gradually introduced. Second, because dose dense MVAC was a relatively new treatment 
option for bladder cancer, there was less available research of outcome for patients at the 
time. Third, the structure of the multidisciplinary meeting has improved during the study 
period, along with the diagnostic pathway that was introduced in 2015. 
 
It is reasonable to think that the current NAC coverage number is closer to the one of the 
later years (around 60%), when the treatment was more established and patient outcome 
better documented. A similar study looking at NAC coverage numbers for MIBC across all 
urological departments in Denmark in the years 2014-2017 showed a coverage of 61% (39). 
In this study however, patients aged above 75 years old were excluded. If we had used the 
same exclusion criteria, the coverage number in our study would rise to 63.4% (45 out of 71 
patients) overall and 82.9% (34 out of 41 patients) in the years 2015-2019. A large study 
across major European centers from 2012 showed that only around 12% of the 5000 
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patients with MIBC included were considered for NAC (34). Another large study, from the 
US, with 7101 patients included, showed that NAC coverage increased from 22.9% to 32.3% 
from 2011 to 2015 (40). It also showed that AC was used quite often, with total 
chemotherapy coverage going from 46.4% to 57.2% in the same years. When looking at 
these studies we see that the NAC coverage in general seems to increase, and that coverage 
at UNN has been relatively extensive in the recent years we studied.  
 
In our study we saw that old age was by far the most important factor for patients not being 
offered NAC, accounting for 50% of cases with MIBC did not offered NAC. The age restriction 
of 75 is not definitive. National guidelines advice that patients above 75 years should be 
thoroughly evaluated before given NAC. In our study there were two patients aged above 75 
who received NAC. 
 
Reduced kidney function and heart disease were also listed frequently, both making up 9.6% 
of cases each. Because MVAC is a cisplatin-based chemotherapy regimen, which is very 
nephrotoxic, there is good reason to be careful when giving this treatment to patients with 
reduced kidney function. The national guidelines recommend that patients with glomerular 
filtration rate (GFR) between 50 and 60 should receive cisplatin over two days, and those 
with GFR below 50 should not be given cisplatin-based chemotherapy. At UNN the limit has 
been set to 45, slightly lower than the national recommendations. Several studies have 
looked at where to draw the line for acceptable kidney function. A study on cisplatin-based 
NAC conducted at the Cleveland Clinic in the US showed that patients with GFR < 60 mL/min 
were less likely to complete all three rounds of chemotherapy and more likely having to 
modify it. It also showed that they had lower pathologic complete response than patients 
with normal kidney function (41). 
 
The advantages of NAC ahead of cystectomy are already well documented as mentioned 
earlier. However, for some patients the cons outweigh the benefits, and they are better off 
without NAC. The difficult part is to select which patients will benefit from the treatment. 
Several studies have looked at ways to identify these patients, and this is still an ongoing 
process, where different biomarkers are being evaluated. 
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Feasibility, side-effects and efficacy 
Of the 47 patients who received NAC, 57.4% underwent all three rounds and 85.1% at least 
two rounds. In the earlier mentioned study from the Cleveland Clinic, 87% of patients with 
GFR > 60 mL/min finished all cycles, while only 70% of patients with GFR between 35 and 59 
finished all cycles, highlighting the fact that renal function is essential for cisplatin-based 
chemotherapy tolerance (41). In our patient group, 75% of patients who received NAC had 
slightly decreased kidney function (creatinine clearance < 90 mL/min/1.73m2) and 23% 
moderately decreased kidney function (creatinine clearance < 60 mL/min/1.73m2), which 
could partly explain why the NAC feasibility was so low in our study. In total, six (30%) of the 
20 patients who discontinued chemotherapy were because of reduced kidney function. 
Consequently, it is advisable to carefully select patients for NAC based on kidney function in 
addition to age and other comorbidities. 
 
Neutropenic sepsis is one of the most feared complications in chemotherapy treatment. In 
our study, neutropenic sepsis was, in total over all three cycles, seen in 8 (17%) out of 47 
patients. A study by Bamias et al. evaluating the toxicity of MVAC, showed that neutropenic 
sepsis occurred in 11.6% of the 109 patients included (42). In this study the MVAC was given 
each four weeks, with a total of six cycles, and all patients received G-CSF. In another study, 
conducted by Von der Maase et al., 12% of patients who received MVAC experienced 
neutropenic sepsis (43). This study also had a slightly different treatment regimen, with 
cycles given each four weeks, and G-CSF was not given routinely, only on indication. Thus, 
neutropenic sepsis was slightly more common in our study. These studies are not truly 
compatible though, since they did not use the dose dense, but rather the standard dose 
MVAC regimen, and number of cycles with chemotherapy and G-CSF administration differs 
from the regimen in our study. Furthermore, the chemotherapy coverage at UNN is quite 
comprehensive compared to other studies. This, probably, means that patients who are in 
worse health and more susceptible to adverse effects are given chemotherapy, which could 
explain some of the increased amount of neutropenic sepsis. Still, a total of 15 (56%) of the 





This study showed a complete pathologic response (tumor downgrade to pT0) in 13 (28%) of 
the 47 patients who received NAC. This is comparable to a study conducted in 2014 by 
Choueiri et al., which showed a complete pathologic response of 26%. Another study, by 
Plimack et al. showed a higher response rate of 38%. A large meta-analysis by Yin et al. 
including a total of 667 patients who received MVAC treatment, showed a complete 
pathological response of 24.3% (26). 
 
In our study, 49% of patients had a histological downgrading of the tumor, while 25.5% had 
no change and 25.5% had an upgrade in tumor stage. In the study performed by Plimack et 
al, these numbers were 65%, 17.5% and 17.5% respectively. However, 93% of patients in 
that study finished all three cycles of chemotherapy, compared to 57.4% in our study. This is 
a plausible explanation for the difference. Also, worth noting is that 57% of included patients 
in that study had more advanced tumor stage than T2, compared to only 4.3% in our study, 
which might affect downgrading percentages. 
 
Surgical complications 
Surgical complications for all 154 patients were 53.2% grade 1-2 complications within 30 
days. Shabsigh et al. conducted a large study including 1142 patients which showed similar 
numbers, with 59.2% of patients experiencing grade 1-2 complications within 30 days (31). 
Grade 3-5 complication on the other hand were significantly higher in our study (24% vs 
11.2%). The reason for this is unknown, however only 12% of patients in the other study had 
priorly received NAC and it was not specified what kind of chemotherapy or how long before 
surgery this was given. 
 
Outcome, relapse and survival 
The actuarial 2-year overall survival was higher for patients treated with NAC (78%) than 
those with no NAC (58%), but not statistically significant since both groups were too small to 
identify any significant differences. Our problem with reduced power due to few included 
cases also in part explain the lack of an association between NAC and improved relapse-free 
and overall survival.  
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A total of seven (14%) of the 52 patients with MIBC who did not receive NAC died of 
treatment complications, compared to only one (2%) of the 49 who received NAC. This is 
quite a substantial difference, but most likely due to patient selection. Patients in the no 
NAC group are patients who, in most cases, were deemed not eligible for NAC due to old age 
and/or extensive comorbidities. Consequentially, patients in this group would probably be 
more susceptible to complications. 
 
Strengths of this study include an unselected study sample, reflecting all patients treated for 
bladder cancer in Troms and Finnmark. Consequently, it also reflects clinical practice. 
Another strength is the registration of complete and comprehensive details for patients 
included. To the best of our knowledge, this is the first study that evaluates chemotherapy 
coverage in this patient group in Norway. 
The main weakness in this study is the small patient group, which causes problems with 
statistical significance and thus type 2 errors. Since patients were not randomized to receive 
chemotherapy or not, this introduces skewness in the way that patients in the no NAC group 
likely were in worse health condition than the NAC group prior to cystectomy. 
 
Conclusion 
Our study showed that total chemotherapy coverage at UNN in the period 2011-2019 was 
47.5%. This number increased greatly during the years we studied and was higher than other 
comparable studies. Old age was by far the most important reason for not receiving 
chemotherapy, followed by heart disease and reduced kidney function. Only 57.4% of 
patients completed all three cycles of chemotherapy. Most frequent reasons for 
discontinuation were reduced kidney function, infection and nausea/anorexia. 
Nausea/anorexia and neutropenic sepsis were the most common complications during 
chemotherapy. Neutropenic sepsis was seen in 17% of patients who received NAC. Given 
that chemotherapy coverage was higher in our study, patients with more extensive 
comorbidity were more likely to be given NAC than in other studies, which could explain why 
feasibility was relatively low and complication rate high. There were no significant 
differences in surgical complications between NAC and no NAC patients. Of the 99 MIBC 
patients, 30% had relapsed at the end of follow-up (June 2020). Chemotherapy did not affect 
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risk of relapse. 2-year overall survival was higher in the NAC group, but not statistically 
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Total number of patients cystectomized at UNN in 
the period 2011-2019. N = 198 
Excluded: 
Patients cystectomized with other histology 
than urotelial carcinoma. N = 39 
Patients with urothelial carcinoma. N = 159 
Excluded: 
Patients who did not have a cystectomy 
for curative purposes. N = 5 
Patients with urothelial carcinoma who had 
a cystectomy for curative purposes. N = 154 
Patients with tumor stage 
lower than T2. N = 55 
Patients with tumor stage T2 and higher. N = 99 
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Figure 1. Incidence (rate per 100 000), mortality and 5-year relative survival (%) for males in 
Norway (1). 
 




















Figure 2. Incidence (rate per 100 000), mortality and 5-year relative survival (%) for females 
in Norway (1). 
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Table 1. Study characteristics at cystectomy for all patients who underwent radical 
cystectomy at UNN during 2011-2019. 







   Male 










Age, median (range), years 70.7 (44.8-88.7) 72.3 (42.6-92.6) 71.8 (42.5-92.6) 
Smoking status 
   Never 
   Previous 













Weight, median (range), kg 75 (52-115) 79 (49.7-122) 77.5 (49.7-122) 
BMI, median (range), kg/m2 24.7 (16.7-33.7) 25.6 (18-35.7) 24.9 (16.7-35.7) 
Creatinine, median (range), µmol/L 92 (47-212) 97 (48-200) 93.5 (47-212) 
Creatinine clearance, median 
(range), µmol/L 
69.9 (26.3-107) 63.7 (29-109.6) 66 (26.3-109.6) 
pT stage before cystectomy 
   Tis 
   T1 
   T2 
   T3 
   T4 






















Type of surgery 
   Open cystectomy 










Data are presented as numbers (%) unless otherwise specified. 
There were missing data for some of the variables: smoking n=2, weight n=2, BMI n=2. 



















Table 2. Study characteristics at cystectomy for muscle-invasive bladder cancer patients who 








   Male 










Age, median (range), years 68.4 (42.5-79.2) 75.2 (53-88.7) 70 (42.5-88.7) 
Smoking status 
   Never 
   Previous 













Weight, median (range), kg 76 (52.5-114) 73 (49.7-115) 77.1 (49.7-115) 
BMI, median (range), kg/m2 24.6 (19.2-34.9) 24.9 (16.7-33.9) 24.7 (16.7-34.9) 
Creatinine, median (range), µmol/L 90 (61-200) 98.5 (47-212) 98.1 (47-212) 
Creatinine clearance, median 
(range), mL/min/1.73m2 
72.3 (29.0-109.6) 60.5 (26.3-107) 64.5 (26.3-
109.6) 
pT stage before cystectomy 
   Tis 
   T1 
   T2 
   T3 
   T4 






















Type of surgery 
   Open cystectomy 










Data are presented as numbers (%) unless otherwise specified. 







Table 3. Reasons for not receiving neoadjuvant chemotherapy. 
Reason Number % 
Old age (>75 years old) 26 50 
Other reasons1 9 17.3 
Other comorbidities2 7 13.5 
Heart disease 5 9.6 
Reduced kidney function 5 9.6 
1 Includes one case of emergency cystectomy due to bleeding and one where the patient did 
not want chemotherapy. No obvious reasons were found in the journal for the remaining 
patients. 
2 Includes diabetes, drug addiction, obesity, other concurrent malignancy, epilepsy and 
duodenal ulcus   
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Table 4. Amount of patients with muscle-invasive bladder cancer who received 
chemotherapy by year. 
    Amount % 
2011 
   Number of patients 








   Number of patients 








   Number of patients 








   Number of patients 








   Number of patients 








   Number of patients 








   Number of patients 








   Number of patients 
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   Number of patients 








  Number of patients  





















Table 5. Reasons for chemotherapy discontinuation for patients who were treated with 
cisplatin-based chemotherapy before cystectomy. 
 After cycle 1 
N=7 
After cycle 2 
N=13 
Reduced kidney function 4 (57.1) 2 (15.4) 
Nausea/anorexia 1 (14.3) 3 (23.1) 
Infection 1 (14.3) 4 (30.8) 
Other1 1 (14.3) 4 (30.8) 
Data are presented as numbers (%) unless otherwise specified. 
1Others include: urethral bleeding, tumor progress, tumor downgraded enough for surgery 













Table 6. Complications during chemotherapy for patients who were treated with cisplatin-
based chemotherapy before cystectomy. 






None 24 (51.1) 26 (65) 22 (81.5) 
Nausea/anorexia 7 (14.9) 8 (20) 2 (7.4) 
Neutropenic sepsis 6 (12.8) 3 (7.5) 2 (11.1) 
Other1 7 (14.9) 3 (7.5) 1 (3.7) 
Reduced kidney function 3 (6.4) 1 (2.5) 0 (0) 
Data are presented as numbers (%) unless otherwise specified. 
Others include: diarrhoea, acid reflux, urinary tract infection, urethral bleeding, problem 











Table 7. Surgical complications follow cystectomy for patients with urothelial bladder cancer. 
Scored using the Clavien-Dindo classification system. Several patients experienced multiple 
complications within one grading category. For these patients we only counted the 
complication we deemed most severe. 






Infection 44 (41.1) 19 (40.4) 63 (40.9%) 
Grade 1-2 within 30 days 
     Infection 
     GI 
     Bleeding/anemia 
     Heart/circulation 
     Wound rupture 






















Grade 3-5 within 30 days 
     Infection 
     GI 
     Bleeding/anemia 
     Heart/circulation 
     Kidney failure 
     Wound rupture 

























Grade 1-2 within 6 months 
     Infection 
     GI 
     Bleeding/anemia 
     Heart/circulation 
     Wound rupture 






















Grade 3-5 within 6 months 
     Infection 
     GI 
     Bleeding/anemia 
     Heart/circulation 
     Wound rupture 
     Kidney failure 

























Data are presented as numbers (%) unless otherwise specified. 





Table 8. Vital status, relapse and causes of death according to NAC vs. no NAC for 99 patients 
with muscle invasive bladder cancer. 






Observation time, years (median, range) 2.1 (0-9.2) 3.0 (0-8.1) 2.6 (0-9.2) 
Vital status 
       Alive without relapse 
       Alive with relapse 
       Overall death 
 
22 (42) 








  4 (4) 
44 (44) 
Relapse, overall 
       Relapse and later dead 
       Relapse and still alive 
14 (27) 
12 (23) 
  2 (4) 
14 (30) 
12 (26) 
  2 (4) 
28 (28) 
24 (24) 
  4 (4) 
Relapse, site specific    
       Regional lymph nodes 
       Lungs 
       Liver 
















Causes of death 
       Bladder cancer (metastatic disease) 
       Treatment-related complications 
       Other causes 
 
14 (27) 
 7 (14) 
  7 (14) 
 
13 (27) 
  1 (2) 
  2 (4) 
 
27 (27) 
  8 (8) 
  9 (9) 
Data are presented as numbers (%) unless otherwise specified.  
For “relapse, site specific”, percentage is derived from the “relapse, overall” number. 
1This group includes the above-mentioned specific sites when there were more than one of 
them present
 
 
 
 
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
